JP2018502834A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502834A5 JP2018502834A5 JP2017529743A JP2017529743A JP2018502834A5 JP 2018502834 A5 JP2018502834 A5 JP 2018502834A5 JP 2017529743 A JP2017529743 A JP 2017529743A JP 2017529743 A JP2017529743 A JP 2017529743A JP 2018502834 A5 JP2018502834 A5 JP 2018502834A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- seq
- antibody
- aml
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 38
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 35
- 230000005945 translocation Effects 0.000 claims description 20
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- 230000035772 mutation Effects 0.000 claims description 14
- 229940124597 therapeutic agent Drugs 0.000 claims description 13
- 210000000349 chromosome Anatomy 0.000 claims description 12
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 10
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 claims description 10
- 101710141832 DNA (cytosine-5)-methyltransferase 3 Proteins 0.000 claims description 10
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 claims description 10
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 claims description 10
- 230000001154 acute effect Effects 0.000 claims description 10
- 238000012423 maintenance Methods 0.000 claims description 10
- 230000005856 abnormality Effects 0.000 claims description 9
- 230000002068 genetic effect Effects 0.000 claims description 9
- 208000032839 leukemia Diseases 0.000 claims description 8
- 210000001726 chromosome structure Anatomy 0.000 claims description 7
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims description 7
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 6
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 6
- 229960003603 decitabine Drugs 0.000 claims description 6
- 229930002330 retinoic acid Natural products 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 6
- 229960001727 tretinoin Drugs 0.000 claims description 6
- 101710168309 CCAAT/enhancer-binding protein alpha Proteins 0.000 claims description 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 5
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims description 5
- 101000945515 Homo sapiens CCAAT/enhancer-binding protein alpha Proteins 0.000 claims description 5
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 5
- 239000003623 enhancer Substances 0.000 claims description 5
- 102000052645 human CD38 Human genes 0.000 claims description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 4
- 102100022678 Nucleophosmin Human genes 0.000 claims description 4
- 108010025568 Nucleophosmin Proteins 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 230000002759 chromosomal effect Effects 0.000 claims description 4
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 3
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims description 3
- 208000033496 Acute myeloid leukaemia with myelodysplasia-related features Diseases 0.000 claims description 3
- 206010008583 Chloroma Diseases 0.000 claims description 3
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 3
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 3
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims description 3
- 208000016544 acute myeloid leukemia with multilineage dysplasia Diseases 0.000 claims description 3
- 229960002756 azacitidine Drugs 0.000 claims description 3
- 210000001185 bone marrow Anatomy 0.000 claims description 3
- 229960002436 cladribine Drugs 0.000 claims description 3
- 239000003246 corticosteroid Substances 0.000 claims description 3
- 229960000684 cytarabine Drugs 0.000 claims description 3
- 229960000975 daunorubicin Drugs 0.000 claims description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 3
- 229960003957 dexamethasone Drugs 0.000 claims description 3
- 229960004679 doxorubicin Drugs 0.000 claims description 3
- 230000004761 fibrosis Effects 0.000 claims description 3
- 238000009093 first-line therapy Methods 0.000 claims description 3
- -1 fludarabin Chemical compound 0.000 claims description 3
- 229960000908 idarubicin Drugs 0.000 claims description 3
- 238000009115 maintenance therapy Methods 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 229960001156 mitoxantrone Drugs 0.000 claims description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 3
- 201000005987 myeloid sarcoma Diseases 0.000 claims description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 230000000306 recurrent effect Effects 0.000 claims description 3
- 229960003087 tioguanine Drugs 0.000 claims description 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 3
- 229960000303 topotecan Drugs 0.000 claims description 3
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 claims description 2
- 108091032955 Bacterial small RNA Proteins 0.000 claims description 2
- 206010050026 Panmyelopathy Diseases 0.000 claims description 2
- 230000000735 allogeneic effect Effects 0.000 claims description 2
- 210000004381 amniotic fluid Anatomy 0.000 claims description 2
- 230000001640 apoptogenic effect Effects 0.000 claims description 2
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 230000001629 suppression Effects 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000036566 Erythroleukaemia Diseases 0.000 claims 1
- 101000708766 Homo sapiens Structural maintenance of chromosomes protein 3 Proteins 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 102100032723 Structural maintenance of chromosomes protein 3 Human genes 0.000 claims 1
- 208000021841 acute erythroid leukemia Diseases 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 26
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 8
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 5
- 102100038501 Splicing factor U2AF 35 kDa subunit Human genes 0.000 description 4
- 101710094463 Splicing factor U2AF 35 kDa subunit Proteins 0.000 description 4
- 108010000597 Polycomb Repressive Complex 2 Proteins 0.000 description 2
- 102000002272 Polycomb Repressive Complex 2 Human genes 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000004676 glycans Chemical group 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462087442P | 2014-12-04 | 2014-12-04 | |
| US62/087,442 | 2014-12-04 | ||
| PCT/US2015/063371 WO2016089960A1 (en) | 2014-12-04 | 2015-12-02 | Anti-cd38 antibodies for treatment of acute myeloid leukemia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020195547A Division JP2021042232A (ja) | 2014-12-04 | 2020-11-25 | 急性骨髄性白血病の治療のための抗ｃｄ３８抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018502834A JP2018502834A (ja) | 2018-02-01 |
| JP2018502834A5 true JP2018502834A5 (OSRAM) | 2020-10-22 |
| JP6802791B2 JP6802791B2 (ja) | 2020-12-23 |
Family
ID=56092366
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529743A Active JP6802791B2 (ja) | 2014-12-04 | 2015-12-02 | 急性骨髄性白血病の治療のための抗ｃｄ３８抗体 |
| JP2020195547A Pending JP2021042232A (ja) | 2014-12-04 | 2020-11-25 | 急性骨髄性白血病の治療のための抗ｃｄ３８抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020195547A Pending JP2021042232A (ja) | 2014-12-04 | 2020-11-25 | 急性骨髄性白血病の治療のための抗ｃｄ３８抗体 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10793630B2 (OSRAM) |
| EP (1) | EP3227338A4 (OSRAM) |
| JP (2) | JP6802791B2 (OSRAM) |
| KR (1) | KR102597989B1 (OSRAM) |
| CN (1) | CN107406506A (OSRAM) |
| AR (1) | AR102921A1 (OSRAM) |
| AU (2) | AU2015358615B2 (OSRAM) |
| BR (1) | BR112017011749A2 (OSRAM) |
| CA (1) | CA2969717A1 (OSRAM) |
| CL (1) | CL2017001382A1 (OSRAM) |
| DO (1) | DOP2017000150A (OSRAM) |
| EA (2) | EA202092609A1 (OSRAM) |
| EC (1) | ECSP17042921A (OSRAM) |
| HK (1) | HK1247221A1 (OSRAM) |
| IL (2) | IL307913A (OSRAM) |
| JO (1) | JO3748B1 (OSRAM) |
| MX (1) | MX2017007208A (OSRAM) |
| NI (1) | NI201700071A (OSRAM) |
| PE (1) | PE20171094A1 (OSRAM) |
| PH (1) | PH12017501042A1 (OSRAM) |
| SG (1) | SG11201704390PA (OSRAM) |
| TW (2) | TWI721959B (OSRAM) |
| UA (1) | UA123697C2 (OSRAM) |
| UY (1) | UY36419A (OSRAM) |
| WO (1) | WO2016089960A1 (OSRAM) |
| ZA (1) | ZA202307128B (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201912554TA (en) * | 2005-03-23 | 2020-02-27 | Genmab As | Antibodies against cd38 for treatment of multiple myeloma |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP2580243B1 (en) | 2010-06-09 | 2019-10-16 | Genmab A/S | Antibodies against human cd38 |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| EA035979B1 (ru) | 2014-09-09 | 2020-09-08 | Янссен Байотек, Инк. | Варианты комбинированной терапии анти-cd38 антителами |
| KR102597989B1 (ko) | 2014-12-04 | 2023-11-02 | 얀센 바이오테크 인코포레이티드 | 급성 골수성 백혈병을 치료하기 위한 항-cd38 항체 |
| IL319936A (en) | 2015-05-20 | 2025-05-01 | Janssen Biotech Inc | Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies |
| WO2016209921A1 (en) | 2015-06-22 | 2016-12-29 | Janssen Biotech, Inc. | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| EP4516319A3 (en) | 2015-11-03 | 2025-05-07 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-cd38 antibodies and their uses |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| MA50514A (fr) | 2017-10-31 | 2020-09-09 | Janssen Biotech Inc | Méthodes de traitement du myélome multiple à haut risque |
| WO2019109095A1 (en) * | 2017-12-01 | 2019-06-06 | Beth Israel Deaconess Medical Center, Inc. | Arsenic trioxide and retinoic acid compounds for treatment of idh2-associated disorders |
| CN113194990A (zh) * | 2018-07-11 | 2021-07-30 | 动量制药公司 | 与靶向CD38的工程化Fc-抗原结合结构域构建体有关的组合物和方法 |
| MX2021002415A (es) | 2018-08-28 | 2021-09-21 | Vor Biopharma Inc | Celulas madre hematopoyeticas modificadas geneticamente y usos de las mismas. |
| CN109265551B (zh) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | Cd38抗体、嵌合抗原受体和药物 |
| GB201916150D0 (en) * | 2019-11-06 | 2019-12-18 | Univ Of Ireland Galway | Treatment of multiple myeloma |
| IL293840A (en) * | 2019-12-13 | 2022-08-01 | Janssen Pharmaceuticals Inc | Methods and devices for delivering liquid therapeutic agents in solid tumors |
| EP4169949A4 (en) * | 2020-06-23 | 2024-08-21 | Jiangsu Kanion Pharmaceutical Co., Ltd. | ANTI-CD38 ANTIBODY AND ITS USE |
| JP2023541457A (ja) | 2020-09-14 | 2023-10-02 | ブイオーアール バイオファーマ インコーポレーテッド | Ｃｄ３８修飾のための化合物および方法 |
| TW202235435A (zh) | 2021-01-14 | 2022-09-16 | 德商莫菲西斯公司 | 抗cd38抗體及其用途 |
| TW202302642A (zh) | 2021-03-01 | 2023-01-16 | 德商莫菲西斯公司 | 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體 |
| JP7767722B2 (ja) | 2021-03-16 | 2025-11-12 | 東ソー株式会社 | ラミネート用延伸ポリエチレンフィルム |
| US20250145730A1 (en) * | 2021-12-16 | 2025-05-08 | Shanghai Bao Pharmaceuticals Co., Ltd. | Anti-immunoglobulin degrading enzyme-digested fc variant |
Family Cites Families (163)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| HUT53672A (en) | 1988-02-25 | 1990-11-28 | Gen Hospital Corp | Quick immunoselective cloning process |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| KR100206524B1 (ko) | 1990-07-13 | 1999-07-01 | 어니스트 엠. 해데드 | 씨디 53 세포 표면 항원 및 그를 암호화하는 재조합 디엔에이 |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| DK0672142T3 (da) | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
| AU6123894A (en) | 1993-01-29 | 1994-08-15 | Board Of Trustees Of The Leland Stanford Junior University | Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto |
| GB9424449D0 (en) | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| JP4233608B2 (ja) | 1996-10-15 | 2009-03-04 | 塩野義製薬株式会社 | 自己抗体測定方法 |
| WO1998016254A1 (en) | 1996-10-17 | 1998-04-23 | Immunomedics, Inc. | Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system |
| WO2000006194A2 (en) | 1997-02-05 | 2000-02-10 | Biotransplant, Inc. | Depletion of cells responsible for antibody-mediated graft rejection |
| WO1998050435A1 (en) | 1997-05-02 | 1998-11-12 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Immunotoxins, comprising an onc protein, directed against malignant cells |
| CA2329940A1 (en) | 1998-06-05 | 1999-12-09 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
| US7223397B1 (en) | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| US6734203B2 (en) | 2000-02-15 | 2004-05-11 | Akira Matsuhisa | Fused imidazolium derivatives |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| WO2001097844A1 (en) | 2000-06-22 | 2001-12-27 | Idec Pharmaceuticals Corporation | Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
| EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| AU1331802A (en) | 2000-10-17 | 2002-04-29 | Trudeau Inst Inc | Cd38 modulated chemotaxis |
| US20070042436A1 (en) | 2000-10-17 | 2007-02-22 | Lund Frances E | CD38 modulated chemotaxis |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| US20040166490A1 (en) | 2002-12-17 | 2004-08-26 | Morris David W. | Novel therapeutic targets in cancer |
| US7550140B2 (en) | 2002-06-13 | 2009-06-23 | Crucell Holland B.V. | Antibody to the human OX40 receptor |
| HUE026914T2 (en) * | 2002-11-07 | 2016-08-29 | Immunogen Inc | Anti-CD33 antibodies and a method of treating acute myeloid leukemia |
| WO2004078140A2 (en) | 2003-03-05 | 2004-09-16 | Halozyme, Inc. | SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF |
| EP1614686B1 (en) | 2003-04-15 | 2014-05-07 | Astellas Pharma Inc. | Bromide and its crystal |
| RS20050885A (sr) | 2003-05-30 | 2008-04-04 | Genentech | Lečenje sa anti-vegf antitelima |
| JP4794301B2 (ja) | 2003-06-11 | 2011-10-19 | 中外製薬株式会社 | 抗体の製造方法 |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| CA2542840A1 (en) | 2003-10-22 | 2005-05-12 | University Of Rochester | Anti-thymocyte antiserum and use thereof to trigger b cell apoptosis |
| PL1684805T3 (pl) | 2003-11-04 | 2010-12-31 | Novartis Vaccines & Diagnostics Inc | Sposoby leczenia szpiczaka mnogiego z zastosowaniem antagonistycznych monoklonalnych przeciwciał przeciwko CD40 |
| ATE536376T1 (de) | 2003-12-23 | 2011-12-15 | Crucell Holland Bv | Humanes bindungsmolekül gegen cd1a |
| EP1720907B1 (en) | 2004-02-06 | 2015-04-08 | MorphoSys AG | Anti-cd38 human antibodies and uses therefor |
| SI2511297T1 (sl) * | 2004-02-06 | 2015-07-31 | Morphosys Ag | Proti -CD38 humana protitelesa in njihova uporaba |
| US20050266008A1 (en) * | 2004-03-29 | 2005-12-01 | Medarex, Inc. | Human anti-IRTA-5 antibodies |
| SG10201912554TA (en) * | 2005-03-23 | 2020-02-27 | Genmab As | Antibodies against cd38 for treatment of multiple myeloma |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| EP2418278A3 (en) | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| TW200745162A (en) | 2005-05-24 | 2007-12-16 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
| CN103554260A (zh) | 2005-10-12 | 2014-02-05 | 莫佛塞斯公司 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
| AU2006329944A1 (en) | 2005-12-09 | 2007-07-05 | Seattle Genetics, Inc. | Methods of using CD40 binding agents |
| CA2646965C (en) | 2006-03-24 | 2016-06-21 | Jonathan H. Davis | Engineered heterodimeric protein domains |
| US20090182127A1 (en) | 2006-06-22 | 2009-07-16 | Novo Nordisk A/S | Production of Bispecific Antibodies |
| HUE026693T2 (hu) * | 2006-08-02 | 2016-07-28 | Sunesis Pharmaceuticals Inc | (+)-1,4-dihidro-7-[(3S,4S)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil) -1,8-naftiridin-3-karbonsav és cytarabin (Ara-C) kombinált alkalmazása leukémia kezelésére |
| WO2008073160A2 (en) | 2006-08-17 | 2008-06-19 | The Trustees Of Columbia University In The City Of New York | Methods for converting or inducing protective immunity |
| PL2081595T3 (pl) | 2006-09-26 | 2019-11-29 | Genmab As | Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| US7618992B2 (en) | 2006-12-29 | 2009-11-17 | Astellas Pharma Inc. | Method of treating cancer by co-administration of anticancer agents |
| MX2009010179A (es) | 2007-03-22 | 2010-03-15 | Imclone Llc | Formulaciones estables de anticuerpo. |
| ES2667863T3 (es) | 2007-03-29 | 2018-05-14 | Genmab A/S | Anticuerpos biespecíficos y métodos de producción de los mismos |
| WO2008121615A2 (en) | 2007-03-30 | 2008-10-09 | Medimmune, Inc. | Antibody formulation |
| JP2010529024A (ja) | 2007-06-01 | 2010-08-26 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｃｒｉｐｔｏ結合分子 |
| EP2535354B1 (en) | 2007-06-18 | 2017-01-11 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| CA2733676A1 (en) * | 2007-08-10 | 2009-02-19 | British Columbia Cancer Agency Branch | Microrna compositions and methods for the treatment of myelogenous leukemia |
| US20090076249A1 (en) | 2007-09-19 | 2009-03-19 | Michel De Weers | Antibodies against CD38 for treatment of multiple myeloma |
| US8748356B2 (en) | 2007-10-19 | 2014-06-10 | Janssen Biotech, Inc. | Methods for use in human-adapting monoclonal antibodies |
| US20110002934A1 (en) | 2007-11-09 | 2011-01-06 | Novartis Ag | Uses of anti-cd40 antibodies |
| WO2009074807A2 (en) | 2007-12-12 | 2009-06-18 | Imperial Innovations Limited | Methods |
| CN101970730A (zh) | 2007-12-19 | 2011-02-09 | 森托科尔奥索生物科技公司 | 通过融合到pⅨ或pⅦ来设计和生成人从头pⅨ噬菌体展示文库,载体、抗体及方法 |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| US8013125B2 (en) | 2008-03-03 | 2011-09-06 | Dyax Corp. | Metalloproteinase 9 and metalloproteinase 2 binding proteins |
| PT4269578T (pt) | 2008-03-06 | 2024-06-18 | Halozyme Inc | Produção em grande escala de hialuronidase solúvel |
| TWI532498B (zh) | 2008-03-17 | 2016-05-11 | 巴克斯特保健公司 | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
| MX2010009647A (es) | 2008-03-25 | 2010-09-28 | Roche Glycart Ag | Uso de un anticuerpo anti-cd20 de tipo ii con citotoxicidad celular dependiente del anticuerpo aumentada en combinacion con ciclofosfamida, vincristina y doxorubicina para el tratamiento de linfoma no hodgkiniano. |
| EP2662090A1 (en) | 2008-04-14 | 2013-11-13 | Halozyme, Inc. | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions |
| TWI394580B (zh) | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
| JP5646457B2 (ja) | 2008-04-29 | 2014-12-24 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリン及びその使用 |
| SI2982696T1 (sl) | 2008-11-07 | 2019-06-28 | Amgen Research (Munich) Gmbh | Zdravljenje akutne limfoblastne levkemije |
| EP2191841A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
| EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| EP2191842A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
| EP2191843A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
| EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| SMT202000092T1 (it) * | 2009-05-14 | 2020-05-08 | Ambit Biosciences Corp | Formulazione essiccata a spruzzo o liofilizzata di ac220 |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| EP2477603B1 (en) | 2009-09-17 | 2016-03-30 | Baxalta Incorporated | Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof |
| JP5898082B2 (ja) | 2009-10-07 | 2016-04-06 | マクロジェニクス，インコーポレーテッド | フコシル化程度の変更により改良されたエフェクター機能を示すＦｃ領域含有ポリペプチドおよびその使用法 |
| EP2327725A1 (en) | 2009-11-26 | 2011-06-01 | InflaRx GmbH | Anti-C5a binding moieties with high blocking activity |
| JP5937523B2 (ja) | 2010-03-01 | 2016-06-22 | サイトダイン インコーポレイテッドＣｙｔｏＤｙｎ， Ｉｎｃ． | 濃縮されたタンパク質製剤およびその使用 |
| GB201003701D0 (en) | 2010-03-05 | 2010-04-21 | Cilian Ag | System for the expression of a protein |
| US20130137134A1 (en) | 2010-03-29 | 2013-05-30 | Ben Gurion University Of The Negev Research And Development Authority | Method and system for detecting and monitoring hematological cancer |
| US9150663B2 (en) | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| EP2580243B1 (en) | 2010-06-09 | 2019-10-16 | Genmab A/S | Antibodies against human cd38 |
| EP2420253A1 (en) | 2010-08-20 | 2012-02-22 | Leadartis, S.L. | Engineering multifunctional and multivalent molecules with collagen XV trimerization domain |
| BR112013006769B1 (pt) | 2010-09-27 | 2021-02-02 | Morphosys Ag | combinação sinérgica |
| RU2604490C2 (ru) | 2010-11-05 | 2016-12-10 | Займворкс Инк. | ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ |
| US9358233B2 (en) * | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| CL2013001944A1 (es) | 2010-12-30 | 2014-09-12 | Takeda Pharmaceutical | Anticuerpo aislado que se une especificamente a cd38 humana y cd38 de cinomolgo; acido nucleico que lo codifica; celula huesped; metodo de produccion; y su uso para tratar una enfermedad autoinmune. |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| DK2688887T3 (en) * | 2011-03-23 | 2015-06-29 | Amgen Inc | DEHYDRATED tricyclic DUALINHIBITORER OF CDK 4/6 AND FLT3 |
| WO2012136732A1 (en) | 2011-04-08 | 2012-10-11 | Ab Science | Treatment of multiple myeloma with masitinib |
| US9993529B2 (en) | 2011-06-17 | 2018-06-12 | Halozyme, Inc. | Stable formulations of a hyaluronan-degrading enzyme |
| EP2747571A4 (en) | 2011-08-24 | 2015-05-27 | David Kerr | COMBINED COMBINED CHEMOTHERAPY |
| EP2561868A1 (en) | 2011-08-24 | 2013-02-27 | Anton Bernhard Van Oosten | Pharmaceutical compositions comprising hydroxychloroquine (HCQ), Curcumin, Piperine/BioPerine and uses thereof in the medical field |
| KR102096224B1 (ko) | 2011-10-28 | 2020-04-03 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 폴리펩티드 구축물 및 이의 용도 |
| WO2013083140A1 (en) | 2011-12-07 | 2013-06-13 | N.V. Nutricia | Beta-lactoglobulin peptides for treating cow's milk protein allergy |
| LT3130347T (lt) | 2011-12-30 | 2019-10-25 | Halozyme Inc | Ph20 polipeptido variantai, kompozicijos ir jų panaudojimas |
| WO2013116307A1 (en) * | 2012-01-30 | 2013-08-08 | Mount Sinai School Of Medicine | Method for programming differentiated cells into hematopoietic stem cells |
| KR101730694B1 (ko) | 2012-03-07 | 2017-04-27 | 카딜라 핼쓰캐어 리미티드 | TNF-α 항체의 약제학적 제형 |
| JP6042527B2 (ja) | 2012-04-04 | 2016-12-14 | ハロザイム インコーポレイテッド | 抗ヒアルロナン剤と腫瘍標的タキサンの組み合わせ治療 |
| KR102702287B1 (ko) | 2012-05-15 | 2024-09-04 | 브리스톨-마이어스 스큅 컴퍼니 | Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법 |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| PL2900232T3 (pl) | 2012-09-25 | 2018-05-30 | Morphosys Ag | Kombinacje i ich zastosowania |
| ES2621377T3 (es) | 2012-11-05 | 2017-07-03 | Morphosys Ag | Anticuerpo marcado radiactivamente y usos del mismo |
| UA118255C2 (uk) | 2012-12-07 | 2018-12-26 | Санофі | Композиція, яка містить антитіло до cd38 і леналідомід |
| EA031025B1 (ru) | 2012-12-21 | 2018-11-30 | Сиэтл Дженетикс, Инк. | Антитела против ntb-a и связанные с ними композиции и способы |
| WO2014142220A1 (ja) | 2013-03-13 | 2014-09-18 | アステラス製薬株式会社 | 抗腫瘍剤 |
| US20140271644A1 (en) | 2013-03-15 | 2014-09-18 | Memorial Sloan-Kettering Cancer Center | Combination/adjuvant therapy for wt-1-positive disease |
| EP2992013B1 (en) | 2013-04-29 | 2019-12-04 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
| US20140356318A1 (en) | 2013-05-28 | 2014-12-04 | Israel Barken | Adoptive cell therapy with specific regulatory lymphocytes |
| CA2919513A1 (en) | 2013-07-15 | 2015-01-22 | Matthew J. Goldstein | Medical uses of cd38 agonists |
| JP2016536361A (ja) | 2013-11-06 | 2016-11-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｄ３３抗体及び脱メチル剤を含む医薬配合物 |
| EP3105317B1 (en) | 2014-02-14 | 2018-09-19 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| WO2015195555A1 (en) | 2014-06-16 | 2015-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells |
| US10106620B2 (en) * | 2014-06-16 | 2018-10-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Blocking CD38 using anti-CD38 F(ab′)2 to protect NK cells |
| US9499514B2 (en) * | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| MA39070A1 (fr) | 2014-07-31 | 2017-11-30 | Sanofi Sa | Anticorps anti-cd38 spécifiques pour le traitement de cancers humains |
| EA035979B1 (ru) | 2014-09-09 | 2020-09-08 | Янссен Байотек, Инк. | Варианты комбинированной терапии анти-cd38 антителами |
| KR102597989B1 (ko) | 2014-12-04 | 2023-11-02 | 얀센 바이오테크 인코포레이티드 | 급성 골수성 백혈병을 치료하기 위한 항-cd38 항체 |
| MA41555A (fr) | 2015-02-17 | 2017-12-26 | Millennium Pharm Inc | Polythérapie pour le traitement du cancer |
| IL319936A (en) | 2015-05-20 | 2025-05-01 | Janssen Biotech Inc | Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies |
| KR20180025888A (ko) | 2015-06-08 | 2018-03-09 | 제넨테크, 인크. | 항-ox40 항체 및 pd-1 축 결합 길항제를 사용하여 암을 치료하는 방법 |
| WO2016209921A1 (en) | 2015-06-22 | 2016-12-29 | Janssen Biotech, Inc. | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
| HRP20240338T1 (hr) | 2015-06-24 | 2024-05-24 | Janssen Biotech, Inc. | Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38 |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| CN107921050A (zh) | 2015-06-29 | 2018-04-17 | 阿布拉科斯生物科学有限公司 | 使用纳米颗粒mtor抑制剂联合疗法治疗血液学恶性肿瘤的方法 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| US20170121417A1 (en) | 2015-11-03 | 2017-05-04 | Janssen Biotech, Inc. | Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses |
| EP4516319A3 (en) | 2015-11-03 | 2025-05-07 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-cd38 antibodies and their uses |
| US20230391884A1 (en) | 2016-06-28 | 2023-12-07 | Umc Utrecht Holding B.V. | Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38 |
| EP3474895A1 (en) | 2016-06-28 | 2019-05-01 | UMC Utrecht Holding B.V. | TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38 |
| US20180117150A1 (en) | 2016-11-01 | 2018-05-03 | Janssen Biotech, Inc. | Combination Therapies for CD38-Positive Hematological Malignances with ANTI-CD38 Antibodies and Cyclophosphamide |
| MA49144A (fr) | 2017-05-18 | 2020-03-25 | Tesaro Inc | Polythérapies pour le traitement du cancer |
| MA50514A (fr) | 2017-10-31 | 2020-09-09 | Janssen Biotech Inc | Méthodes de traitement du myélome multiple à haut risque |
| AU2019244478B2 (en) | 2018-03-28 | 2025-11-06 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-CD38 antibodies |
| US20190298827A1 (en) | 2018-04-03 | 2019-10-03 | Janssen Biotech, Inc. | Methods of Treating Multiple Myeloma |
| JOP20200292A1 (ar) | 2018-05-16 | 2020-11-15 | Stichting Vumc | Bcma / cd3 و gprdc5d / cd3 مضادات غير محددة للاستخدام في علاج السرطان |
| BR112021007227A2 (pt) | 2018-10-17 | 2021-08-10 | Janssen Biotech, Inc. | método para fornecer administração subcutânea de anticorpos anti-cd38 |
| EP3880824B1 (en) | 2018-11-13 | 2024-07-24 | Janssen Biotech, Inc. | Control of trace metals during production of anti-cd38 antibodies |
| US20200268847A1 (en) | 2019-02-22 | 2020-08-27 | Janssen Biotech, Inc. | Methods of Treating Newly Diagnosed Multiple Myeloma with a Combination of An Antibody that Specifically Binds CD38, Lenalidomide and Dexamethasone |
| US20200308296A1 (en) | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone |
| US20200316197A1 (en) | 2019-03-28 | 2020-10-08 | Janssen Biotech, Inc. | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone |
| US20200308297A1 (en) | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses |
| WO2020194243A1 (en) | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with lenalidomide and dexamethasone |
| US20200330593A1 (en) | 2019-03-28 | 2020-10-22 | Janssen Biotech, Inc. | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib, Mephalan and Prednisone |
| US20200405854A1 (en) | 2019-04-19 | 2020-12-31 | Janssen Biotech, Inc. | Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses |
| US20200397896A1 (en) | 2019-04-19 | 2020-12-24 | Janssen Biotech, Inc. | Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses |
| US20200392242A1 (en) | 2019-04-19 | 2020-12-17 | Janssen Biotech, Inc. | Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses |
| WO2020243911A1 (zh) | 2019-06-04 | 2020-12-10 | 上海科技大学 | Nad+和/或nad+抑制剂和/或nad+激动剂的用途及其联合制剂 |
| US20220275101A1 (en) | 2021-02-09 | 2022-09-01 | Janssen Biotech, Inc. | Use of Approved Anti-CD38 Antibody Drug Product to Treat Light Chain Amyloidosis |
| US20220275090A1 (en) | 2021-02-22 | 2022-09-01 | Janssen Biotech, Inc. | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors |
-
2015
- 2015-12-02 KR KR1020177017757A patent/KR102597989B1/ko active Active
- 2015-12-02 WO PCT/US2015/063371 patent/WO2016089960A1/en not_active Ceased
- 2015-12-02 TW TW104140257A patent/TWI721959B/zh active
- 2015-12-02 CN CN201580075548.5A patent/CN107406506A/zh active Pending
- 2015-12-02 IL IL307913A patent/IL307913A/en unknown
- 2015-12-02 EP EP15865128.1A patent/EP3227338A4/en active Pending
- 2015-12-02 US US14/956,890 patent/US10793630B2/en active Active
- 2015-12-02 BR BR112017011749A patent/BR112017011749A2/pt not_active Application Discontinuation
- 2015-12-02 SG SG11201704390PA patent/SG11201704390PA/en unknown
- 2015-12-02 JP JP2017529743A patent/JP6802791B2/ja active Active
- 2015-12-02 EA EA202092609A patent/EA202092609A1/ru unknown
- 2015-12-02 MX MX2017007208A patent/MX2017007208A/es unknown
- 2015-12-02 UA UAA201706786A patent/UA123697C2/uk unknown
- 2015-12-02 AU AU2015358615A patent/AU2015358615B2/en active Active
- 2015-12-02 HK HK18106919.5A patent/HK1247221A1/zh unknown
- 2015-12-02 CA CA2969717A patent/CA2969717A1/en active Pending
- 2015-12-02 PE PE2017000966A patent/PE20171094A1/es unknown
- 2015-12-02 TW TW110104368A patent/TWI775309B/zh active
- 2015-12-02 EA EA201791208A patent/EA037084B9/ru unknown
- 2015-12-03 JO JOP/2015/0298A patent/JO3748B1/ar active
- 2015-12-04 AR ARP150103977A patent/AR102921A1/es unknown
- 2015-12-04 UY UY0001036419A patent/UY36419A/es not_active Application Discontinuation
-
2017
- 2017-05-29 IL IL252568A patent/IL252568A0/en unknown
- 2017-05-30 CL CL2017001382A patent/CL2017001382A1/es unknown
- 2017-06-02 NI NI201700071A patent/NI201700071A/es unknown
- 2017-06-05 PH PH12017501042A patent/PH12017501042A1/en unknown
- 2017-06-22 DO DO2017000150A patent/DOP2017000150A/es unknown
- 2017-07-05 EC ECIEPI201742921A patent/ECSP17042921A/es unknown
-
2020
- 2020-08-27 US US17/005,039 patent/US12286474B2/en active Active
- 2020-11-25 JP JP2020195547A patent/JP2021042232A/ja active Pending
-
2021
- 2021-08-17 AU AU2021218021A patent/AU2021218021B2/en active Active
-
2023
- 2023-07-17 ZA ZA2023/07128A patent/ZA202307128B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502834A5 (OSRAM) | ||
| US11124582B2 (en) | FLT3L-FC fusion proteins | |
| TWI823906B (zh) | 抗-cd73 抗體及其使用方法 | |
| ES2962674T3 (es) | Inhibidores PD-1/PD-L1 | |
| JP7560575B2 (ja) | 抗体－薬物コンジュゲート及びその調製物 | |
| JP2018520101A5 (OSRAM) | ||
| JP2017507954A5 (OSRAM) | ||
| AU2022298639C1 (en) | Diacylglyercol kinase modulating compounds | |
| US11976072B2 (en) | Diacylglycerol kinase modulating compounds | |
| BR112019012483A2 (pt) | conjugados de fármaco de anticorpo para ablar células-tronco hematopoiéticas | |
| CN105749276A (zh) | Cd37抗体在cll血液样品中的优良效力 | |
| JP2022530202A (ja) | Ｔｏｌｌ様受容体モジュレーターの固体形態 | |
| JP7682104B2 (ja) | 非小細胞肺がんを処置するための方法および組成物 | |
| US20190322695A1 (en) | 2'3'-cyclic dinucleotides | |
| US20230279106A1 (en) | Antigen Binding Proteins | |
| JP7715041B2 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| JP2024536133A (ja) | 抗ｈｓｐ７０抗体およびその治療的使用 | |
| WO2023143444A1 (zh) | 抗dkk1抗体、其药物组合物及用途 | |
| JP2024513264A (ja) | Ｎｋｐ４６及びｇｐｃ３を標的とする二重特異性抗体、並びにその使用方法 | |
| EA048410B1 (ru) | Выделенное биспецифическое антитело, которое специфически связывается с cd47 и pd-l1 | |
| HK40071848A (en) | Flt3l-fc fusion proteins and methods of use | |
| EA045919B1 (ru) | СЛИТЫЕ БЕЛКИ FLT3L-Fc И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| CN117794522A (zh) | 抗cd19抗体和帕萨昔布的组合疗法 | |
| CA3248580A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES AND DISORDERS CAUSED BY EOSINOPHIL ACTIVITY | |
| NZ732753B2 (en) | Anti-cd38 antibodies for treatment of acute myeloid leukemia |